Probatebeta
Target

AVPR2

Vasopressin V2 receptor

As of the edition of 20 October 2026, AVPR2 (vasopressin V2 receptor, UniProt P30518) has 13 drugs tested at it and 21 companies on the list, 3 on route A and 2 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P30518
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
44
Disease areas
Urinary and reproductive; Pregnancy and women's health; Hormones; Heart and blood vessels; Nutrition and metabolism; Digestive system; Inherited and neonatal; Nervous system
Registered trials of its drugs
338

Drugs at this target

StatusCount
Marketed9
Went quiet2
Stopped2
Total13
DrugStatusFurthest phaseUS protection
TolvaptanMarketedPhase 4Ended 2026
DesmopressinMarketedPhase 4none listed
VasopressinMarketedPhase 4none listed
TerlipressinMarketedPhase 4Ends 2029
ConivaptanMarketedPhase 4none listed
LixivaptanStoppedPhase 3none listed
SatavaptanStoppedPhase 3none listed
FedovapagonWent quietPhase 3none listed
Argipressin tannateMarketedPhase 4none listed
PecavaptanWent quietPhase 2none listed
LypressinMarketedNo phase statednone listed
MozavaptanMarketedNo phase statednone listed

12 of 13 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A3
Route B2
Engaged2
Undetermined14
Total on the list21
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
Palladio BiosciencesRoute A
Byk-Mallinckrodt CILRoute B

The other 18 companies at AVPR2

In the product

21 companies in all; 18 are not named here, and no score is.

See the 21 companies at AVPR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in urinary and reproductive

Companies holding approvals at AVPR2